Skip to main content
Premium Trial:

Request an Annual Quote

German Proteomics Company Publishes Paper Detailing Use of Proprietary Fingerprinting Technology

NEW YORK, July 2 – German proteomics company MelTec said Monday its scientists have published a paper in the June 5 issue of IEEE Transactions  describing how the company’s Neuronal Cell Detection System can be used to monitor fluorescent lymphocytes in human tissue.

In the paper, “A Neural Classifier Enabling High-Throughput Topological Analysis of Lymphocytes in Tissue Section,” the researchers explain that by using robotic imaging technology they were able to read protein networks in cells and analyze how these networks encode for cellular function.

The article describes that by using MelTec's NCDS algorithm, the biomathematical basis of its proprietary robotic imaging technology known as Multi-Epitope-Ligand-Kartographie, or MELK, the researchers were able to automatically monitor in tissues the number of fluorescent marked migratory cells, the positions of these cells, and the phenotype of these cells.

The NCDS system enabled researchers to conduct high-throughput, reproducible and valid statistical analysis of protein networks involved in disease pathways, MelTec said.

"The NCDS provides a unique tool for analyzing proteomic information that was not available before, linking cellular structure, protein expression and function," Walter Schubert, MelTec’s CEO, said in a statement. "Our system has the potential to become a key technology that paves the way for a more systematic approach to understanding disease pathology and treatment, by looking at how protein networks in cells determine cellular function.”

According to the study, the NCDS is capable of detecting and monitoring at least 85 percent of the cells involved in tissue migration and the protein networks that participate in the involved mechanisms. MelTec said that by understanding cellular migration, it believes that it can better understand diseases such as cancer and arteriosclerosis. 

MelTec is a privately held company based in Magdeburg, Germany. Its MELK technology is designed to perform automated proteomic characterization of single cells and for hundreds of proteins simultaneously.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.